Recludix Pharma Inc. has obtained IND clearance from the FDA to advance REX-8756 (SAR-448755), an oral STAT6 inhibitor for inflammatory diseases, into phase I testing. REX-8756 is an oral, selective STAT6 inhibitor that employs a novel therapeutic approach by targeting STAT6’s SH2 domain.
Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular disorders, viral infections, neurodegeneration, and autoimmune, metabolic and liver diseases, among others.
Hangzhou Baicreat Pharma-Tech Co. Ltd. has disclosed oxamide compounds acting as signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders.
Deepcure Inc. has nominated DC-15442, an oral selective STAT6 inhibitor, as its second development candidate. DC-15442 is designed to replicate the safety and efficacy of dupilumab, while offering an oral alternative to regular subcutaneous injections.
Recludix Pharma Inc. has nominated a lead development candidate, REX-8756, an oral, selective and reversible small-molecule inhibitor of STAT6, and completed GLP toxicology studies for the compound. REX-8756 has potential for patients with type 2 immune-related inflammatory diseases.
Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors targeting STAT6 may help prevent and treat allergic diseases, asthma, atopic dermatitis or other Th2-driven immune conditions. Researchers from Recludix Pharma Inc. have presented the preclinical profiles of REX-8756 and REX-4671, two STAT6 inhibitors being developed in partnership with Sanofi SA.
Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.
Enanta Pharmaceuticals Inc. has announced the expansion of its immunology portfolio with the nomination of a new development candidate and the introduction of a new discovery program.
